HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Burton, Durbin Chairmanships End; DSHEA Reform May Still Garner Interest

This article was originally published in The Tan Sheet

Executive Summary

Rep. Dan Burton (R-Ind.) will step down as chairman of the House Government Reform Committee after his six-year term expires in December

You may also be interested in...



NNFA Slashes Retailer Dues To Attract New Members, Build Clout On Hill

NNFA is attempting to attract 7,000 potential retailer members, or roughly 15,000 stores, by cutting annual dues for independent stores and small chains to a flat $30 fee

Multivitamin, Weight-Loss Product Studies Reviewed At Govt. Reform Hearing

New research data on the effects of daily multivitamin use on cardiovascular disease risk factors, as well as CDC survey findings on consumption of weight-loss products, were highlighted during a House Government Reform Committee hearing July 25

FDA ephedrine alkaloids adverse reaction data requested by House subcommittee.

EPHEDRINE ADVERSE EVENT DATA REQUESTED BY HOUSE SUBCOMMITTEE in a Dec. 10 letter from Government Reform & Oversight/Human Resources Subcommittee Chairman Christopher Shays (R-Conn.) to FDA Lead Deputy Commissioner Michael Friedman, MD. "The Subcommittee on Human Resources is investigating the circumstances prompting [FDA's] proposed rule on maximum ephedrine alkaloid dosages," Shays states. FDA published its proposed rule on ephedrine alkaloids in the June 4 Federal Register ("The Tan Sheet" June 9, pp. 20-23).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS131055

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel